Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)
Open accessThe DOI matches its Crossref record, with a small difference in title or year.
Abstract
Background: A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19infection in the United Kingdom from November 2020 with a transmission advantage over the previous variants of the virus. Here we report efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19, against this variant in comparison with non-B.1.1.7 lineages. Methods: Volunteers enrolled in phase II/III vaccine efficacy studies in the United Kingdom and randomised 1:1 to receive ChAdOx1 nCoV-19 or a MenACWY control vaccine, providedupper airway swabs every week during the trial and also if they developed possible symptomatic COVID-19 infection. Swabs were tested by nucleic acid amplification test (NAAT) for SARS-CoV-2, and positive samples were sequenced through the COVID-19Genomics UK consortium (COG UK). NAAT data were used to assess the duration ofdetectable viral RNA in diagnostic specimens and the viral load. Anti-spike IgG wasmeasured by ELISA at baseline, 14 and 28 days after prime and 28 days after boostervaccination. Neutralising antibody responses were measured using a live virus neutralisation assay against the B.1.1.7 and Victoria lineages of the virus. The efficacy analysis included symptomatic COVID-19 in seronegative participants with a NAAT positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cut-off on Jan 14, 2021. Vaccine efficacy was calculated as 1 − relative risk derived from a robust Poisson regression model. This study is ongoing and is registered with ClinicalTrials.gov NCT04400838 and ISRCTN 15281137.5 Findings: Between 1st October 2020 and 14th January 2021, 499 participants developed Covid-19infection. 1524 NAAT positive nose/throat swabs were collected from these participants during the trial. Of these, 323 swabs from 256 participants were successfully sequenced.ChAdOx1 nCoV-19 recipients had a significantly lower viral load as represented byminimum PCR Ct value (p<0.0001) and were NAAT positive for a shorter time (p<0.0001) than participants who received the control vaccine. Virus neutralisation activity by vaccineinduced antibodies was 9-fold lower against the B.1.1.7 variant than against a canonical non B.1.1.7 lineage. Vaccine efficacy against symptomatic NAAT positive infection was similar for B.1.1.7 and non-B1.1.7 lineages (74.6% [95%CI 41.6-88.9] and 84% [95% CI 70.7-91.4] respectively). There was no difference in anti-spike antibody titres between individuals who had received a prior ChAdOx1 vectored vaccine and those who were naïve to ChAdOx1. Interpretation: Efficacy of ChAdOx1 nCoV-19 against the B.1.1.7 variant of SARS-CoV-2 is similar to the efficacy of the vaccine against other lineages. Furthermore, vaccination with ChAdOx1 nCoV-19 results in a reduction in the duration of shedding and viral load, which may translate into a material impact on transmission of disease. Trial Registration Number: This study is ongoing and is registered with ClinicalTrials.gov NCT04400838 and ISRCTN 15281137. Funding: The clinical trial was funded by UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, NIHR OxfordBiomedical Research Centre, Thames Valley and South Midlands NIHR Clinical Research Network, and AstraZeneca. COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome SangerInstitute. Computational work was supported by the Wellcome Trust Core Award Grant Number 203141/Z/16/Z with funding from the NIHR Oxford BRC. Conflict of Interest: Oxford University has entered into a partnership with AstraZeneca for further development of ChAdOx1 nCoV-19. AstraZeneca reviewed the data from the study and the final manuscript before submission, but the authors retained editorial control. SCG is cofounder of Vaccitech (collaborators in the early development of this vaccine candidate) and named as an inventor on a patent covering use of ChAdOx1-vectored vaccines (PCT/GB2012/000467) and a patent application covering this SARS-CoV-2 vaccine. TL is named as an inventor on a patentapplication covering this SARS-CoV-2 vaccine and was consultant to Vaccitech. PMF is a consultant to Vaccitech. AJP is Chair of the UK Department of Health and Social Care’s JCVI, but does not participate in policy advice on coronavirus vaccines, and is a member of the WHO Strategic Advisory Group of Experts (SAGE). AJP and SNF are NIHR SeniorInvestigators. AVSH is a cofounder of and consultant to Vaccitech and is named as aninventor on a patent covering design and use of ChAdOx1-vectored vaccines(PCT/GB2012/000467). MDS reports grants from Janssen, GlaxoSmithKline, Medimmune,Novavax, and MCM Vaccine and grants and non-financial support from Pfizer outside of the submitted work. CG reports personal fees from the Duke Human Vaccine Institute outside of the submitted work. ADD reports grants and personal fees from AstraZeneca outside of the submitted work. SNF reports grants from Janssen and Valneva, outside the submitted work.TLV and JV are employees of AstraZeneca. All other authors declare no competing interests.The views expressed in this publication are those of the authors and not necessarily those of the National Institute for Health Research or the Department of Health and Social Care. Ethical Approval: The study was sponsored by the University of Oxford (Oxford, UK) and approved in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) reference 21584/0428/001-0001 and the South-Central Berkshire Research Ethics Committee reference 20/SC/0179.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is now clinical evidence that the ChAdOx1 nCoV-19 Oxford-AstraZeneca and NVX-CoV2373 Novavax vaccines provide protection from B.1.1.7 (Emary et al., 2021; Mahase, 2021).”
From Antibody evasion by the P.1 strain of SARS-CoV-2 (2021) · cites this paper as Emary et al., 2021
Citations
Cited by
Hall, V. J., Foulkes, S., Saei, A., Andrews, N., Oguti, B., Charlett, A., Wellington, E., Stowe, J., Gillson, N., Atti, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00790-x · Cited by 767
Hall, V. J., Foulkes, S., Charlett, A., Atti, A., Monk, E. J. M., Simmons, R., Wellington, E., Cole, M. J., Saei, A., Oguti, B., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00675-9 · Cited by 638
Antibody evasion by the P.1 strain of SARS-CoV-2
Dejnirattisai, W., Zhou, D., Supasa, P., Liu, C., Mentzer, A. J., Ginn, H. M., Zhao, Y., Duyvesteyn, H. M. E., Tuekprakhon, A., Nutalai, R., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.055 · Cited by 583
“There is now clinical evidence that the ChAdOx1 nCoV-19 Oxford-AstraZeneca and NVX-CoV2373 Novavax vaccines provide protection from B.1.1.7 (Emary et al., 2021; Mahase, 2021).”
InfluentialSARS-CoV-2 variants and ending the COVID-19 pandemic
Fontanet, A., Autran, B., Lina, B., Kieny, M. P., Karim, S. S. A., & Sridhar, D. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00370-6 · Cited by 519
Mohammed, I., Nauman, A., Paul, P., Ganesan, S., Chen, K.-H., Jalil, S. M. S., Jaouni, S. H., Kawas, H., Khan, W. A., Vattoth, A. L., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2027160 · Cited by 406
“is an ongoing, multicenter, single-blinded trial in phase 2/3, conducted in the UK where participants aged 18 or above are randomized 1:1 to receive either the Oxford/AstraZeneca vaccine or a control meningococcal vaccine (Men ACWY).(46) The aim of the study was to determine the efficacy of the Oxford/AstraZeneca vacc…”
BackgroundMethodResultInfluentialTauzin, A., Nayrac, M., Benlarbi, M., Gong, S. Y., Gasser, R., Beaudoin-Bussières, G., Brassard, N., Laumaea, A., Vézina, D., Prévost, J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.001 · Cited by 167
“, 2020); however, recent observations suggest that they might not be predictive, on their own, of protection (Emary et al., 2021; Luchsinger and Hillyer, 2021).”
Bager, P., Wohlfahrt, J., Fonager, J., Rasmussen, M., Albertsen, M., Michaelsen, T. Y., Møller, C. H., Ethelberg, S., Legarth, R. A., Button, M. S. F., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00290-5 · Cited by 144
Acuña‐Zegarra, M. A., Díaz‐Infante, S., Baca-Carrasco, D., & Olmos‐Liceaga, D. (2021) · Mathematical Biosciences · doi:10.1016/j.mbs.2021.108614 · Cited by 137
Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?
Tiboni, M., Casettari, L., & Illum, L. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120686 · Cited by 128
SARS-CoV-2 vaccines: a triumph of science and collaboration
Golob, J. L., Lugogo, N. L., Lauring, A. S., & Lok, A. S.-F. (2021) · JCI Insight · doi:10.1172/jci.insight.149187 · Cited by 123
Wang, H., Miller, J. A., Verghese, M., Sibai, M., Solis, D., Mfuh, K. O., Jiang, B., Iwai, N., Mar, M., Huang, C., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.00859-21 · Cited by 99
Viral Vectors for COVID-19 Vaccine Development
Lundstrom, K. H. (2021) · Viruses · doi:10.3390/v13020317 · Cited by 108
COVID-19 vaccines for low- and middle-income countries
Choi, E. M.-L. (2021) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1093/trstmh/trab045 · Cited by 94
Status Report on COVID-19 Vaccines Development
Kumar, A., Dowling, W. E., Román, R. G., Chaudhari, A. B., Gurry, C., Le, T. T., Tollefson, S., Clark, C. E., Bernasconi, V., & Kristiansen, P. A. (2021) · Current Infectious Disease Reports · doi:10.1007/s11908-021-00752-3 · Cited by 86
SARS-CoV-2: is there neuroinvasion?
McQuaid, C., Brady, M., & Deane, R. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-021-00267-y · Cited by 74
Revealing the Threat of Emerging SARS-CoV-2 Mutations to Antibody Therapies
Chen, J., Gao, K., Wang, R., & Wei, G. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167155 · Cited by 76
Safety of ChAdOx1 nCoV-19 Vaccine: Independent Evidence from Two EU States
Riad, A., Pokorná, A., Mekhemar, M. K., Conrad, J., Klugarová, J., Koščík, M., Klugar, M., & Attia, S. (2021) · Vaccines · doi:10.3390/vaccines9060673 · Cited by 66
“Unlike the mRNA vaccines, adenovirus vector vaccines do not require ultra-low storage temperature and, therefore, could be feasiblly distributed and delivered [5].”
BackgroundChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7
Fischer, R. J., van Doremalen, N., Adney, D. R., Yinda, C. K., Port, J. R., Holbrook, M. G., Schulz, J. E., Williamson, B. N., Thomas, T., Barbian, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26178-y · Cited by 62
Vaccine rollout strategies: The case for vaccinating essential workers early
Mulberry, N., Tupper, P. F., Kirwin, E. M., McCabe, C. J., & Colijn, C. (2021) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000020 · Cited by 69
“As well, substantial reduction in viral loads have been found among those who become infected after receiving either the AstraZeneca vaccine [10] or the BioNTech/Pfizer BNT162b2 vaccine [11,12], suggesting reduced transmission even when infection does occur.”
BackgroundA Systematic Review of the Sex and Gender Reporting in COVID-19 Clinical Trials
Heidari, S., Palmer-Ross, A., & Goodman, T. (2021) · Vaccines · doi:10.3390/vaccines9111322 · Cited by 57
“AstraZeneca ** [60] II/III No No No No No 3009 million”
BackgroundEfficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and ReportsPreprint
Shapiro, J., Dean, N. E., Madewell, Z. J., Yang, Y., Halloran, M. E., & Longini, I. M. (2021) · medRxiv · doi:10.1101/2021.05.20.21257461 · Cited by 51
Lumley, S. F., Rodger, G., Constantinides, B., Sanderson, N., Chau, K. K., Street, T. L., O’Donnell, D., Howarth, A., Hatch, S. B., Marsden, B. D., et al. (2021) · medRxiv · doi:10.1101/2021.03.09.21253218 · Cited by 48
“7, despite evidence of decreased neutralising titres, but decreased efficacy for asymptomatic/unknown symptom infections.(35) Pfizer-BioNTech vaccine effectiveness in HCWs appears preserved despite increasing B.”
BackgroundImmunity to SARS-CoV-2: Lessons Learned
FERGIE, J. E., & Srivastava, A. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654165 · Cited by 50
Profiles of current COVID-19 vaccines
Heinz, F. X., & Stiasny, K. (2021) · Wiener klinische Wochenschrift · doi:10.1007/s00508-021-01835-w · Cited by 47
Monitoring differences between the SARS-CoV-2 B.1.1.7 variant and other lineages
Jewell, B. L. (2021) · The Lancet Public Health · doi:10.1016/s2468-2667(21)00073-6 · Cited by 36
VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants
Prates-Syed, W. A., Chaves, L. C. S., Crema, K. P., Vuitika, L., Lira, A. A. D. L., Côrtes, N., Kersten, V., Guimarães, F. E. G., Sadraeian, M., da Silva, F. L. B., et al. (2021) · Vaccines · doi:10.3390/vaccines9121409 · Cited by 39
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7Preprint
Fischer, R. J., van Doremalen, N., Adney, D. R., Yinda, C. K., Port, J. R., Holbrook, M. G., Schulz, J. E., Williamson, B. N., Thomas, T., Barbian, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.11.435000 · Cited by 30
Imai, N., Hogan, A. B., Williams, L. R., Cori, A., Mangal, T. D., Winskill, P., Whittles, L. K., Watson, O. J., Knock, E., Baguelin, M., et al. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16992.1 · Cited by 25
The method utilized to purify the SARS-CoV-2 N protein can affect its molecular properties
Tarczewska, A., Kolonko, M., Zarębski, M., Dobrucki, J. W., Ożyhar, A., & Greb‐Markiewicz, B. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.08.026 · Cited by 19
“…structure of the N protein is highly conserved and not vulnerable to mutations, which is especially interesting in the context of the appearance of new SARS-CoV-2 variants that are resistant to some of the newly developed “spike protein-targeted” vaccines (Liu et al, 2021)(Emary et al, 2021).”
Song, F., & Bachmann, M. O. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-053507 · Cited by 18
An update on host immunity correlates and prospects of re-infection in COVID-19
Negi, N., Maurya, S. P., Singh, R., & Das, B. K. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.2019727 · Cited by 23
SARS-CoV-2 Variants: Mutations and Effective Changes
Park, G., & Hwang, B. H. (2021) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-021-0327-3 · Cited by 17
Vaccination for COVID-19: Is it important and what should you know about it?
Wu, C.-P., Adhi, F., & Culver, D. A. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.ccc076 · Cited by 8
Hunziker, P. (2021) · Precision Nanomedicine · doi:10.33218/001c.26101 · Cited by 7
Impffortschritt in Deutschland und der Welt: Chancen und Risiken
Grimm, V., Lembcke, F. K., & Schwarz, M. (2021) · Wirtschaftsdienst · doi:10.1007/s10273-021-2894-5 · Cited by 5
Ge, A., Rioux, M. L., & Kelvin, A. A. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.25.437035 · Cited by 3
“7 compared to others, although further analysis is still needed due to small numbers in study participants [54,55].”
ResultProbiotics mediated control and immunomodulation of SARS-CoV-2 associated pathological conditions
Kumari, P. S., Viswapriya, V., Rajakumari, M. L., & Murugan, S. (2021) · Annals of Phytomedicine An International Journal · doi:10.21276/ap.covid19.2021.10.1.16 · Cited by 1
The course of the UK COVID 19 pandemic; no measurable impact of new variantsPreprint
Ellis, D., Papadopoulos, D., Mukherjee, S. K., Ukwu, U., Chari, N., Charitopoulos, K., Donkov, I., & Bishara, S. (2021) · medRxiv · doi:10.1101/2021.03.16.21253534 · Cited by 2
Marco, A., Teixidó, N., Guerrero, R., Puig, L., Rué, X., Cobo, A., Barnés, I., & Turú, E. (2021) · medRxiv · doi:10.1101/2021.08.03.21258337 · Cited by 2
Broad human and animal coronavirus neutralisation by SARS-CoV-2 S2-targeted vaccinationPreprint
Ng, K. W., Faulkner, N., Finsterbusch, K., Wu, M., Harvey, R., Hussain, S., Greco, M., Liu, Y., Kjær, S., Swanton, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.30.470568 · Cited by 1
8 vragen over het AstraZenecavaccin
Wapenaar, J. (2021) · Nursing · doi:10.1007/s41193-021-0044-5
Hunziker, P. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3794249
Metadata
- Authors
- Emary, K. R. W., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B. J., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., Clutterbuck, E., Collins, A. M., Cox, T., Darton, T., Dold, C., Douglas, A. D., Duncan, C. J. A., Ewer, K., Flaxman, A., Faust, S. N., Ferreira, D. M., Feng, S., Finn, A., Folegatti, P. M., Fuskova, M., Galiza, E., Goodman, A. L., Green, C. M., Green, C. A., Greenland, M., Hallis, B., Heath, P. T., Hay, J., Hill, H. C., Jenkin, D., Kerridge, S., Lazarus, R., Libri, V., Lillie, P. J., Ludden, C., Marchevsky, N. G., Minassian, A. M., McGregor, A. C., Farooq Mujadidi, Y., Phillips, D. J., Plested, E., Pollock, K. M., Robinson, H., Smith, A., Song, R., Snape, M. D., Sutherland, R. K., Thomson, E. C., Toshner, M., Turner, D. P. J., Vekemans, J., Villafana, T. L., Williams, C. J., Hill, A. V. S., Lambe, T., Gilbert, S. C., Voysey, M., Ramasamy, M. N., Pollard, A. J., Consortium, A., & Group, O. C. V. T.
- Affiliations
- University of Oxford (GB)
- University of Cambridge (GB)
- Public Health England (GB)
- Liverpool School of Tropical Medicine (GB)
- University of Sheffield (GB)
- Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
- NIHR Southampton Biomedical Research Centre (GB)
- University of Liverpool (GB)
- University of Bristol (GB)
- St George's, University of London (GB)
- University College London (GB)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- University of London (GB)
- Queen Elizabeth University Hospital (GB)
- University Hospitals Bristol and Weston NHS Foundation Trust (GB)
- University of Hull (GB)
- Genomics England (GB)
- London North West Healthcare NHS Trust (GB)
- Imperial College London (GB)
- Western General Hospital (GB)
- MRC University of Glasgow Centre for Virus Research (GB)
- Nottingham University Hospitals NHS Trust (GB)
- AstraZeneca (United Kingdom) (GB)
- AstraZeneca (United States) (US)
- Aneurin Bevan University Health Board (GB)
- Centre for Human Genetics (GB)
- Corresponding author
- Ramasamy, Maheshi N.
- ORCID
- Emary, Katherine R. W.
- Golubchik, Tanya
- Aley, Parvinder K.
- Ariani, Cristina V.
- Angus, Brian John
- Bibi, Sagida
- Blane, Beth
- Bonsall, David
- Cicconi, Paola
- Charlton, Sue
- Clutterbuck, Elizabeth
- Collins, Andrea M.
- Darton, Thomas
- Dold, Christina
- Douglas, Alexander D.
- Duncan, Christopher J. A.
- Ewer, Katie
- Flaxman, Amy
- Faust, Saul N.
- Ferreira, Daniela M.
- Feng, Shuo
- Finn, Adam
- Folegatti, Pedro M.
- Fuskova, Michelle
- Galiza, Eva
- Goodman, Anna L.
- Green, Catherine M.
- Green, Christopher A.
- Greenland, Melanie
- Hallis, Bassam
- Heath, Paul T.
- Hay, Jodie
- Hill, Helen C.
- Jenkin, Daniel
- Kerridge, Simon
- Lazarus, Rajeka
- Libri, Vincenzo
- Lillie, Patrick J.
- Ludden, Catherine
- Marchevsky, Natalie G.
- Minassian, Angela M.
- McGregor, Alastair C.
- Farooq Mujadidi, Yama
- Phillips, Daniel J.
- Plested, Emma
- Pollock, Katrina M.
- Robinson, Hannah
- Song, Rinn
- Snape, Matthew D.
- Sutherland, Rebecca K.
- Thomson, Emma C.
- Toshner, Mark
- Turner, David P. J.
- Vekemans, Johan
- Villafana, Tonya L.
- Williams, Christopher J.
- Hill, Adrian V. S.
- Lambe, Teresa
- Gilbert, Sarah C.
- Voysey, Merryn
- Ramasamy, Maheshi N.
- Pollard, Andrew J.
- Venue
- SSRN Electronic Journal
- Publisher
- Elsevier BV
- Published
- 2021
- ISSN
- 1556-5068 (ISSN-L)
- OpenAlex
- W3081849522
- Cited by
- 43
- References
- 0
- Citations by year
- 2022: 1 · 2021: 42
- Type
- posted content
- Language
- en
- Open access
- green
- doi.org
- Locations
- SSRN Electronic Journal (acceptedVersion)
- Funders
- Medical Research Council (MC_UU_00004/04)
- Engineering and Physical Sciences Research Council (EP/R013756/1)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- ChAdOx1 nCoV-19 vaccine, AZD1222, SARS-CoV-2, B.1.1.7 variant, vaccine efficacy, adenovirus vector vaccine, COVID-19 pandemic, viral load, viral shedding, neutralizing antibodies, anti-spike IgG, viral genome sequencing, breakthrough infection, Omicron variant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.